Sun Pharmaceutical Industries kundali

Sun Pharmaceutical Industries (SUNPHARMA, Healthcare) was incorporated on 1 March 1993. This page shows its birth chart, its dasha periods since listing and how the share moved in each.

Sun Pharmaceutical Industries birth chart

Lagna Mesha, lagna lord Mangal in the 3rd house. Moon in Vrishabha, Rohini pada 1.

Sun Pharma's past: what lifted it and what pressed on it

A deal-maker whose best gains follow its hardest tests

Sun Pharmaceutical Industries is a company built by acquisition, and its chart describes exactly that. It is strong in the house of gains and in the house of work, but it carries its heaviest tests in the houses of struggle and loss. The history confirms this. The share has grown from Rs 1.2 in November 1996 to Rs 1,880 today, a rise of 1,55,272%. It reached its highest close of Rs 2,001 in July 2026. Its biggest advances came after it took on large, difficult deals, and its worst years came when those deals were being digested.

This reading follows the company from 1 March 1993, the date of incorporation for which the chart is cast, to today, period by period. It stays with the past and says nothing about what lies ahead.

The one idea it keeps returning to is simple. In this chart, gains come out of pressure. When Sun Pharma takes on strain, whether a large merger, a regulatory cloud or a change in plan, it tends to come out bigger. Where the share went against that pattern, the reading says so plainly.

Strong earner, steady worker, with a hard side to manage

The chart has four placements that shape how this company does business. The houses are indicative, because the hour of incorporation is not on record, while the Moon and the dasha periods are firm.

First, Shani, the planet of discipline, sits in its own sign in the house of work and rules both work and gains. This is the chart's backbone. It explains a company that earns steadily and keeps its books clean. Today debt is only 0.03 times equity, operating profit covers interest 51.2 times, and the company holds Rs 17,675 crore more cash than debt. CRISIL reaffirmed its AAA rating on 13 October 2026.

Second, the Moon is exalted in the house of income, with Ketu beside it. The exalted Moon gives a strong earning base. Ketu tends to cause sudden breaks and sharp reversals. Revenue is Rs 61,631 crore over twelve months, up 11.9% in the year to September 2026, yet profit fell 36.2% in the same year. Peers did far better on both counts, at 22.5% and 15.3%. The base is sound, but the gains are not smooth.

Third, Guru, the planet of expansion, sits in the house of struggle and rules the house of loss, while Budh, the planet of trade, sits weak in the house of loss. This is a pattern in which gains come out of crises. The Ranbaxy deal of 2014-15 is the clearest case. The company agreed to buy Ranbaxy in a $4 billion all-share deal and completed it on 25 March 2015. The share then lagged the Nifty badly, falling 48% at its worst point between 2014 and 2017. Later years repaid the effort.

Fourth, the house of leadership is helped by Shani but the house of contracts and partners is the weakest in the chart. The company has filed 6 management change notices in the past year, including the CFO change of 6 May 2025. That tells you the top team is where pressure shows first.

Moon years: a young company's first great climb

The Moon's period, from November 1996 to March 2002, was the stretch in which Sun Pharmaceutical first showed what it could do. The share rose 942% across these five years, and the adjusted price began at Rs 1.2. Most of that came in a single burst in 1999. Other years were flat or slightly negative.

The reason is simple. Chandra, the Moon, is exalted in this chart, sitting in the house of wealth and speech. An exalted Moon gives a company a base that grows steadily and draws the public's trust. It rules the house of property and assets, which is why this early period built value rather than headlines.

The chart does not claim every year was good. 1997 and 2000 both ended lower, and the share fell as much as 30% to 39% inside three of the five sub-periods. For an investor, the lesson is that this company rewarded patience, but not smoothly. Each sub-period below reads differently.

A slow start with a 37% drop on the way

From November 1996 to January 1998 the share rose 26%, but not in a straight line. At its worst point inside the period it was down 37%. The calendar year 1997 closed 3.5% lower at Rs 1.36, so the gain came mostly in the final months. FACTS records no merger, acquisition or other filing dated in these months.

Shani, Saturn, is the lord of this sub-period. In this chart it sits strong in its own sign in the house of work and standing, and it also rules the house of gains. Saturn pays slowly and makes a company earn its returns first. That fits a small company still building its name.

For an investor, this stretch shows how the company behaves under pressure. It lost over a third of its value at the low point, yet it finished ahead. The gain was modest, and the chart says plainly that this was a period of patience, not reward.

The share doubles as 1998 builds strength

From January 1998 to June 1999 the share rose 103%, an ample gain by any measure. It still fell 39% at its worst point inside the period, so the climb was uneven. The year 1998 closed 25% higher at Rs 1.7. By the end of June 1999 the share was set for the larger run that followed. FACTS has no dated company event inside these months.

Budh, Mercury, rules this sub-period. In this chart it is debilitated, but it rules the house of effort and the house of competition and debts, and it sits in the house of loss, where hard-won gains can come out of difficulty. Mercury is the planet of trade and commerce, which suits a company that sells medicines in volume.

The lesson for an investor is that this company grew fastest when it was hardest to hold. A 39% fall, followed by a doubling, is the pattern the chart describes as gains that come out of crises. The pattern would return in later decades.

Eight months that more than tripled the share

From June 1999 to January 2000 the share rose 232%. This is the best sub-period in the whole history of Sun Pharmaceutical. Even then it fell 30% at its worst point inside the period. The calendar year 1999 ended 535.3% higher at Rs 10.8. FACTS records no merger or other filing dated in these months, so the rise was the market's response to the business itself.

Ketu, the shadow planet of detachment, rules this sub-period. It sits with the exalted Moon in the house of wealth. Ketu does not rule a house, so it takes on the character of the Moon beside it. That brought a sudden, almost unexplained run of confidence, which is how Ketu usually acts.

An investor should read this as both a gift and a warning. The company can deliver an extraordinary run in a short time, and a 30% shake-out arrived inside the same months. Gains of this size did not come again in such a short span.

Twenty months of digesting the 1999 surge

From January 2000 to September 2001 the share rose only 8%. After the burst of 1999 the share went sideways. The year 2000 closed 4.8% lower at Rs 10.28, and 2001 closed 7.7% higher at Rs 11.07. The sharpest single day was 19 May 2000, a rise of 11%, which stood out in a quiet stretch. FACTS has no dated company event here.

Shukra, Venus, rules this sub-period. It is exalted in this chart and rules the house of wealth and the house of partnerships. It also sits in the house of loss beside Budh. Venus tends to bring comfort and consolidation, not speed, which matches a company pausing after a rush.

The lesson is that a strong chart does not mean a rising share every year. After a 232% gain, the company spent nearly two years doing little. An investor who bought at the January 2000 peak waited a long time for any return, which the chart does not dispute.

A short, steady close to the Moon years

From September 2001 to March 2002 the share rose 14% in six months. This was a calm finish with no deep fall recorded. FACTS records no merger, acquisition or other event dated inside it. The Moon's long period closed with the share well above where it began in 1996.

Surya, the Sun, rules this sub-period. It sits in the house of gains, which brings income, though in a sign it does not like. It rules the house of intelligence and past merit. The Sun gives authority and a clear direction, and a short period under it often closes accounts rather than opens new ones.

What this tells an investor is that Sun Pharmaceutical left its first great era on a steady note rather than a crash. The next period, under Mars, began with a 15% fall in the first five months, so the calm did not carry over. The company moved from one stretch to the next without a break in its direction.

Mars years: seven years that multiplied the share sixfold

The Mars major period ran from March 2002 to March 2009 and was the stretch in which Sun Pharma grew from a small drug maker into a serious name. The share rose 581% across it, with only two sub-periods ending lower. Mergers and demergers arrived in 2006 and 2007.

The chart reason is simple. Mangal, the planet of drive and effort, rules the first house, which stands for the company itself, and also the eighth, which stands for sudden change. Here Mangal sits in the house of effort and initiative, so the period rewarded the company for pushing hard. The eighth-house side showed up as sharp swings, most of all in 2008.

A flat start: the share slips 15% in five months

The period opened badly. From March to August 2002 the share fell 15%. No merger, acquisition or other major event is recorded in these months, so this was a plain loss of momentum rather than a reaction to news.

The reason is that Mangal's own sub-period brings its themes in raw form: the first house of the company's standing, and the eighth house of upheaval. The first sub-period of any major period often starts with a restless phase before the real direction shows, and that is what happened here. We have no results for 2002, so no company figure can be set against it.

For an investor, the lesson is that this company did not need a smooth beginning to do well. The 15% fall in five months was the only weak patch before a long climb. The year 2002 still closed up 5.9%, so the early dip was recovered inside the calendar year. Sun Pharma's early record shows a pattern: a quiet or poor opening, then recovery once the next phase begins.

Rahu's year: the share climbs 74% as the company widens

From August 2002 to August 2003 the share rose 74%. Calendar 2003 added 100.5%, one of the best years in the record. No filing marks a corporate event here, so the gain came from the business itself being rewarded.

Rahu is the planet of appetite and rapid expansion. In this chart it sits in the eighth house, the house of sudden change, and it hands its results through Mangal, who runs the period. Rahu's phases tend to reward bold, outward-looking moves, and Sun Pharma was then building its reach beyond India.

What this tells an investor is that the company grows fastest when the chart gives it room to reach out. This was the first strong proof of that. The share doubled in a year with no merger or announcement to explain it, which says the market was responding to steady business growth. This gain went with the chart, not against it.

Guru's year: a steady 52% gain as the base builds

Between August 2003 and July 2004 the share rose 52%. Calendar 2004 closed up 87.9%, so the climb went on past the sub-period. No merger or acquisition falls inside these months.

Guru, the planet of expansion and good fortune, is the strongest graha in this chart. He rules the ninth house of luck and the twelfth of overseas links, and he sits in the sixth house of competition. That placement gives gains that come through facing rivals, which suits a generic drug maker selling in crowded markets.

Compared with the Rahu year, this was calmer. The rise was smaller and came without a severe drop recorded inside the period. For an investor, it shows Guru's periods give Sun Pharma slower, sturdier progress. Where Rahu produced a sprint, Guru produced a steady build that the next phases could stand on.

Shani's turn: discipline pays, the share gains 81%

From July 2004 to September 2005 the share rose 81%, the best of the middle sub-periods. Calendar 2005 added a smaller 23.4%, because much of the gain landed in late 2004. No corporate event is filed in this window.

Shani, the planet of discipline and slow reward, is in his own sign in the tenth house of work and standing. He also rules the eleventh house of gains. A strong Shani in the house of work is the chart's clearest support for steady operations, and this period paid for years of patient effort.

The lesson for an investor is that Sun Pharma's best returns often come when it is working hard rather than announcing deals. Here there were no mergers and no headlines, yet the share gained 81%. That was a plain reward for running the business well, and it happened in the same planet's phase that later brought harder tests under Rahu.

Budh's year: the first demerger and a 46% gain

Between September 2005 and September 2006 the share rose 46%, though at one point it was 26% below its starting level. On 7 June 2006 the company filed a Scheme of Arrangement with Sun Pharma Advanced Research Company, a demerger of the research arm.

Budh, the planet of trade and dealings, rules the third house of effort and the sixth of competition. In this chart he is debilitated, sitting in the twelfth house, so his results come with friction. The sharp drop inside the year and the restructuring both fit that picture: gains arrived, but after a rough patch.

An investor can take two things from this. First, Sun Pharma began using corporate restructuring as a tool in this period, a habit that grew over the next fifteen years. Second, this chart's gains often follow a scare. The 26% dip was real, but the year still closed well ahead, and the share's rise held up.

Ketu's short pause: the share adds only 13%

From September 2006 to February 2007 the share rose 13%. It was the shortest and quietest sub-period of the era, running just five months. No merger, acquisition or other event is recorded in the window, and no severe fall is noted.

Ketu is the planet of detachment and letting go. He sits in the second house of income, beside the exalted Moon. Ketu's phases tend to hold the company in a pause, where effort goes inward rather than into visible growth. The modest gain matches that.

For an investor, this stretch shows that Sun Pharma could take a pause without losing ground. A small gain after the demerger of 2006 suggests the company was digesting that change. It was a breathing space between the busy Budh year and the fuller Venus phase that followed. Calendar 2006 had closed up 45.1%, so the pause sat on top of a good year.

Venus year: a court-approved scheme and a 28% gain

Between February 2007 and April 2008 the share rose 28%, though it fell 25% at its worst point inside the period. On 5 April 2007 the filing records that the Gujarat High Court approved a Scheme of Arrangement, heard on 1 March 2007. Calendar 2007 closed up 32.8%.

Shukra, the planet of comfort and money, rules the second house of income and the seventh of partnerships. He is exalted in the twelfth house, and the chart marks a Dhana yoga, a wealth combination, between him and Guru. A court-approved scheme fits the seventh-house side, which governs formal agreements.

For an investor, the 25% fall inside the year shows that a good period does not mean a smooth ride. Even with the combination at work, the share was shaken before it recovered. The takeaway is that Sun Pharma's wealth gains come with temporary losses, and holders needed patience to sit through them.

Surya's short spell: the share outruns a falling market

From April to August 2008 the share rose 16% while the Nifty fell 5%. Calendar 2008 closed with Sun Pharma down 11%, far better than the Nifty's 51.8% loss. The gain here came before the market collapse.

Surya, the Sun, is the planet of authority and rules the fifth house of intellect and strategy. He sits in the eleventh house of gains, in a sign that does not suit him, yet that house still gave this period its lift. A well-placed house of gains explains why the share moved against a weak market.

The reading for an investor is about resilience. As global markets weakened, Sun Pharma's business of everyday medicines held up better than the average listed company. That 21-point gap over the Nifty in four months foreshadowed how the company would behave in the crash that followed, which the next period shows.

Chandra's crash year: down 32%, yet ahead of the Nifty

The period closed with the worst stretch of the whole record. From August 2008 to March 2009 the share fell 32%, and at its worst point it was 37% below its start. The Nifty fell 43% in the same months. On 5 November 2008 the share jumped 10.5% in one day, a relief rally inside the slide.

Chandra, the Moon, is exalted in the second house of income here, so the chart gave the company protection even as the world market broke. He rules the fourth house of stability and assets, which is why the share lost less than the market. The fall itself was driven by the global crash, not by anything recorded about the company.

For an investor, the 11-point gap over the Nifty is the point. Sun Pharma fell hard but fell less. Then Rahu's major period began in March 2009, and the share rose 162% over the next two years and eight months. The worst stretch also set the base for the best that followed.

Rahu years: eighteen years of deals and a twenty-fold rise

The Rahu major period ran from March 2009 to November 2026, and the share rose 2,088% across it. It brought Sun Pharma its largest deals, a long slump after the Ranbaxy merger, and a strong recovery into 2024.

Rahu is the planet of appetite and foreign reach. In this chart it sits in the 8th house, the house of sudden change and things that come through others' hands. That explains the pattern: growth by taking over other companies, and shocks that arrived without warning.

The sub-periods below show how each phase treated the business. Two periods, Rahu–Mercury and Rahu–Saturn, trailed the Nifty badly. The others beat it.

Post-crash rebound that outran the Nifty

From March 2009 to November 2011 the share rose 162%, against 91% for the Nifty. It fell 31% at its worst point. The sharpest day was 18 May 2009, up 22%. On 26 June 2009 it lost 11.64% in one day. The calendar years show the swing: up 43% in 2009 and 62% in 2010, then only 3.4% in 2011, though the Nifty fell 24.6% that year.

The reason is Rahu acting on its own sign-lord Mangal, which rules the 1st and 8th houses. That brings fast moves and sharp reversals, with recovery after a crisis. This was the first stretch after the 2008 fall, and it began by climbing out of that hole.

For an investor, this stretch shows a company that recovers faster than the market once a panic ends. It also showed that the climb came with sudden drops, so the path was never smooth.

Guru years: bonus issue and the Ranbaxy deal

From November 2011 to April 2014 the share rose 155%, against 38% for the Nifty. The company issued a 1:1 bonus on 29 July 2013 and approved another restructuring on 14 November 2013. On 7 April 2014 it agreed to buy Ranbaxy in a $4 billion all-share deal.

Guru, the planet of expansion, rules the 9th and 12th houses here and sits in the 6th, the house of competitors and debts. That placement gives gains that come out of tough conditions, a pattern the chart marks as a viparita raja yoga. The Ranbaxy bid fits it: a large takeover of a company in difficulty.

For an investor, this was the period that set Sun Pharma's scale. It shows that the company acts boldly when times favour expansion. Here the share and the chart agreed closely, with the share more than four times as strong as the Nifty.

Saturn's slow years after the takeover

From April 2014 to February 2017 the share rose only 8%, while the Nifty gained 30%. It fell 48% at its worst. On 25 March 2015 the Ranbaxy merger was completed. On 21 July 2015 the share lost 15% in a day, its worst single day on record. The years read: up 45.9% in 2014, flat in 2015, then down 23.1% in 2016.

Shani, the planet of discipline and delay, rules the 10th house of work and the 11th of gains. It sits strongly in its own sign, so it demands effort before it pays. Integrating a large acquisition fits that: heavy work, slow rewards.

For an investor, this stretch shows what swallowing a big rival costs. The share lagged the market and the chart does not explain the fall in 2016 as sharply as the delay in gains. The lesson is that a big deal here takes years to pay off.

Mercury years: the longest underperformance

From February 2017 to September 2019 the share fell 36%, while the Nifty rose 24%. It dropped 48% at its worst point. On 29 May 2017 it fell 11% in a day. On 4 September 2019 the exchange sought clarification on a news report of a regulator's interest, and the share slid. Several restructuring schemes were approved along the way.

Budh, the planet of trade and numbers, is the weakest planet in this chart. It is debilitated and sits in the 12th house of losses. It rules the 3rd and 6th houses, so its period brings friction with rivals, regulators and costs.

For an investor, this was the hardest stretch, and the share clearly went against the market. It shows that this company's weak point is regulatory and legal pressure, and that such pressure can weigh for more than two years.

A short pause with a pandemic-year gain

From September 2019 to September 2020 the share rose 16%, against 1% for the Nifty. It fell 29% at its worst point inside the period. On 27 December 2019 an NCLT order on a scheme of arrangement came through, and on 29 July 2020 the company made an acquisition. The year 2020 closed up 38.2%.

Ketu is the planet of detachment and release. It sits in the 2nd house of wealth beside the exalted Moon, which protects the company's reserves. A Ketu period clears old matters, and here that meant tidying group structure and a drop-and-recover pattern.

For an investor, this showed a company that held up in the 2020 crash better than the market. The cash-rich balance sheet, with about ₹17,675 crore more cash than debt today, fits that steadiness.

Venus years: three strong years of gains

From September 2020 to September 2023 the share rose 138%, against 78% for the Nifty. A scheme of arrangement was sanctioned by the NCLT on 16 September 2021. The share closed up 44.4% in 2021, 19.7% in 2022 and 27.2% in 2023, beating the Nifty each year.

Shukra, the planet of comfort and income, is exalted in the 12th house and rules the 2nd house of wealth and the 7th of partnerships. It joins Guru in a wealth-creating yoga. That is the reason the business earned steadily and the share rose without a deep fall.

For an investor, this is the clearest proof that the company does well when Shukra's period supports it: steady growth without big deals or disputes. Chart and share agreed here.

Sun years carried the share to new highs

From September 2023 to August 2024 the share rose 58%, against 26% for the Nifty. The year 2024 closed up 51.1%, the best calendar year since 2010, with the Nifty at 8.8%. No major deal or dispute is dated inside the period.

Surya, the planet of authority, sits in the 11th house of gains and rules the 5th house of skill and creativity. It is in an enemy sign, yet it is among the chart's two strongest planets. That fits a stretch where the gains came from the company's own product strength.

For an investor, this shows that Sun Pharma can rise on its own operations alone, without an acquisition to lift it. Specialty drugs such as Ilumya and Leqselvi have since kept that theme alive.

Moon years: a flat spell and a new finance chief

From August 2024 to February 2026 the share fell 1%, against a 3% gain for the Nifty. The year 2025 closed down 8%, while the Nifty rose 10.5%. On 6 May 2025 the company announced a change of Chief Financial Officer.

Chandra, the Moon, is exalted in the 2nd house and rules the 4th, the house of assets and comfort. It sits with Ketu, which dulls its gains. That fits a pause: a strong balance sheet, but little reward.

For an investor, this stretch shows that a flat share did not mean a weak business. Debt stands at 0.03 times equity and operating cash is 1.08 times profit. The period was a rest, and the share trailed the market without a crisis.

Mars year: a modest gain and mixed results

From February 2026 to November 2026 the share rose 10%, against a 1% fall for the Nifty. Its highest close, ₹2,001, came in July 2026, and it fell to ₹1,740 in October. Over the twelve months to September 2026 profit fell 36.2% while revenue rose 11.9%, behind the 22.5% and 15.3% for the median healthcare company.

Mangal, the planet of energy and conflict, rules the 1st and 8th houses but sits in an enemy sign in the 3rd. That gives drive and effort, with friction. October brought two director resignation filings and a clarification on news about the Assam facility.

For an investor, this period shows a company with strong cash and a CRISIL AAA rating reaffirmed on 13 October 2026, but with profit under pressure. The share outpaced the market even as earnings lagged.

Each big corporate event had a planet behind it

Looking only at the named events in the record, three planets keep returning: Guru, Shani and Budh. Each brings its own kind of event to this company, and the chart gives a reason for each.

Guru, the planet of expansion, runs most of the deal-making. Its sub-periods hold the 29 July 2013 bonus issue of 1:1 and the 13 November 2013 board resolution on a merger, both under Rahu–Guru. The 7 April 2014 agreement to buy Ranbaxy in a $4 billion all-share deal also fell in Rahu–Guru. The earlier schemes of 7 June 2006 and 5 April 2007 sat in Mangal–Budh–Guru and Mangal–Shukra–Shukra. The reason is simple. Guru rules the 9th house of fortune and the 12th house of overseas links in this chart, and it sits in the 6th house of competition. Growth here comes by taking on a rival, which is exactly what the Ranbaxy purchase was.

Shani, the planet of discipline, carries the completion of deals. It is strong in the 10th house of work and rules the houses of work and gains. The High Court approval of 30 July 2014 came in Rahu–Shani–Shani. The board resolution of 13 November 2014 came in Rahu–Shani–Budh. The Ranbaxy merger was completed on 25 March 2015 in Rahu–Shani–Ketu. The acquisition and the Global FZE merger approval of 29 and 31 July 2020 fell in Rahu–Ketu–Shani, and the 6 May 2025 change of Chief Financial Officer in Rahu–Chandra–Shani. Shani is slow, so its events are approvals, paperwork and people in key posts, not sudden jumps.

Budh, the planet of trade and paperwork, is the chart's weakest planet. It sits debilitated in the 12th house. Its sub-periods hold the restructuring schemes of 14 August 2017, 14 November 2017, 25 May 2018 and 3 December 2018. The same stretch holds the one allegation in the record: on 4 September 2019 the exchange sought clarification on a news report about a SEBI probe, in Rahu–Budh–Shani. Budh rules the 6th house of disputes as well as the 3rd, so a weak Budh brings frequent restructuring and an occasional question from a regulator.

Other events are single. The 1 March 1993 incorporation fell in Chandra–Mangal–Guru and the 8 February 1995 listing in Chandra–Guru–Guru. The 20 September 2021 sanction came in Rahu–Shukra–Mangal, and the 30 May 2022 amalgamation in Rahu–Shukra–Guru.

For an owner of this company, the lesson is that the chart marks deal windows and tells them apart from the windows of scrutiny. Guru brings the big move, Shani brings its completion, and Budh brings the clean-up and the questions that follow.

Which planets paid Sun Pharma, which pressed on it

Read across thirty years, the pattern is plain. Sun Pharma grows fastest when the periods of Ketu, Guru and Shani carry the load, and it struggles when Budh's period runs. Budh is the planet of trade and accounts, and it is the weakest graha in this chart. That is the thread to hold on to.

The evidence is in the periods. Moon–Ketu from June 1999 to January 2000 gave +232%, the best stretch on record. Mars–Saturn added 81% and Mars–Rahu 74%. Rahu–Jupiter gave 155% against 38% for the Nifty, and Rahu–Venus gave 138% against 78%. Budh's two periods tell the other side. Rahu–Mercury, from February 2017 to September 2019, fell 36% while the Nifty rose 24%, and it carried the 4 September 2019 clarification over a regulator report. Rahu–Saturn also lagged, at 8% against 30%, with a 48% fall inside it. Mars–Moon, the worst stretch at −32%, fell during the 2008 crash, and it still held up better than the Nifty's −43%.

The share has not always followed the chart. Rahu–Moon from August 2024 to February 2026 was flat at −1%, though the chart called it a supportive period for the business. The present record bears out the strong side. Debt is only 0.03 times equity, the company holds ₹17,675 crore more cash than debt, and CRISIL reaffirmed its AAA rating on 13 October 2026. Revenue is up 11.9% on the year. The weaker side also shows. Profit is down 36.2% against a peer median of 15.3% up, and six management-change filings came in the year. The chart's strength lies in the balance sheet and in recovery after hard tests, and its pressure falls on profit and on the top team.

The coming periods, with their dates and what each holds for the business, are read in the full reading.

Sun Pharmaceutical Industries: common questions

When was Sun Pharmaceutical Industries incorporated?

Sun Pharmaceutical Industries was incorporated on 1 March 1993. Its kundali is cast for that date.

What is Sun Pharmaceutical Industries's lagna and Moon sign?

Sun Pharmaceutical Industries's chart rises in Mesha, with its lord Mangal in the 3rd house. The Moon is in Vrishabha, Rohini pada 1.

Which dasha is Sun Pharmaceutical Industries running now?

Sun Pharmaceutical Industries is in the Rahu mahadasha and the Mangal antardasha, which runs until 9 March 2027. The sub-period inside it, Shukra, ends on 17 January 2027.

When did Sun Pharmaceutical Industries list on the NSE?

Sun Pharmaceutical Industries listed on the National Stock Exchange on 8 February 1995.

Which graha rules Sun Pharmaceutical Industries's sector?

Sun Pharmaceutical Industries is in Healthcare. In the classical scheme the sector is ruled by Ketu for research-led pharma, with Rahu for chemicals. Its strength in transit sets the sector's weather; Sun Pharmaceutical Industries's own chart shows how the company is built for it.

Does GrahaEdge give buy or sell calls on Sun Pharmaceutical Industries?

No. GrahaEdge reads the company's chart and history. It gives no share-price targets and no buy, sell or hold calls.